Alkermes (ALKS) to Release Quarterly Earnings on Wednesday

Alkermes (NASDAQ:ALKS - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of $0.81 per share and revenue of $379.74 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Alkermes Price Performance

Shares of ALKS traded down $0.34 during midday trading on Monday, reaching $31.23. The stock had a trading volume of 1,751,551 shares, compared to its average volume of 1,433,998. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $5.05 billion, a price-to-earnings ratio of 16.02, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company's 50-day moving average is $30.08 and its 200 day moving average is $28.60. Alkermes has a 12-month low of $22.90 and a 12-month high of $32.88.

Insider Buying and Selling at Alkermes

In related news, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Craig C. Hopkinson sold 100,918 shares of the company's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now owns 44,290 shares of the company's stock, valued at $1,419,494.50. This trade represents a 69.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,189 shares of company stock valued at $5,723,518 in the last 90 days. Insiders own 4.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Stifel Nicolaus upgraded shares of Alkermes from a "hold" rating to a "buy" rating and increased their price target for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. JPMorgan Chase & Co. reduced their target price on shares of Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Mizuho boosted their price target on shares of Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reduced their price objective on Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Finally, The Goldman Sachs Group decreased their price objective on Alkermes from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.